Attach to Form 990 or Form 990-EZ.
See separate instructions.| (i) Name of supported organization |
(ii) EIN |
(iii) Type of organization (described on lines 1- 9 above or IRC section (see instructions)) |
(iv) Is the organization in col. (i) listed in your governing document? |
(v) Did you notify the organization in col. (i) of your support? |
(vi) Is the organization in col. (i) organized in the U.S.? |
(vii) Amount of support? |
|||
|---|---|---|---|---|---|---|---|---|---|
| Yes | No | Yes | No | Yes | No | ||||
| Total | |||||||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") .... | 22,038,265 | 30,491,706 | 20,760,601 | 22,553,697 | 22,876,129 | 118,720,398 |
| 2 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf....... | ||||||
| 3 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 4 | Total. Add lines 1 through 3.. | 22,038,265 | 30,491,706 | 20,760,601 | 22,553,697 | 22,876,129 | 118,720,398 |
| 5 | The portion of total contributions by each person (other than a governmental unit or publicly supported organization) included on line 1 that exceeds 2% of the amount shown on line 11, column (f).. | 5,841,089 | |||||
| 6 | Public Support. Subtract line 5 from line 4. | 112,879,309 | |||||
| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 7 | Amounts from line 4.. | 22,038,265 | 30,491,706 | 20,760,601 | 22,553,697 | 22,876,129 | 118,720,398 |
| 8 | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | 822,092 | 842,799 | 643,473 | 668,573 | 951,963 | 3,928,900 |
| 9 | Net income from unrelated business activities, whether or not the business is regularly carried on.. | ||||||
| 10 | Other income. (Explain in Part IV.) Do not include gain or loss from the sale of capital assets.. | 20,042 | 4,177,745 | 117,005 | 2,317,760 | 1,492,968 | 8,125,520 |
| 11 | Total support (Add lines 7 through 10). | 130,774,818 | |||||






| Calendar year(or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 1 | Gifts, grants, contributions, and membership fees received. (Do not include any "unusual grants.") . | ||||||
| 2 | Gross receipts from admissions, merchandise sold or services performed, or facilities furnished in any activity that is related to the organization's tax-exempt purpose...... | ||||||
| 3 | Gross receipts from activities that are not an unrelated trade or business under section 513.. | ||||||
| 4 | Tax revenues levied for the organization's benefit and either paid to or expended on its behalf... | ||||||
| 5 | The value of services or facilities furnished by a governmental unit to the organization without charge.. | ||||||
| 6 | Total. Add lines 1 through 5. | ||||||
| 7a | Amounts included on lines 1, 2, and 3 received from disqualified persons... | ||||||
| b | Amounts included on lines 2 and 3 received from other than disqualified persons that exceed the greater of $5,000 or 1% of the amount on line 13 for the year. | ||||||
| c | Add lines 7a and 7b.. | ||||||
| 8 | Public Support (Subtract line 7c from line 6.) | ||||||
| Calendar year (or fiscal year beginning in) | (a) 2006 | (b) 2007 | (c) 2008 | (d) 2009 | (e) 2010 | (f) Total | |
|---|---|---|---|---|---|---|---|
| 9 | Amounts from line 6... | ||||||
| 10a | Gross income from interest, dividends, payments received on securities loans, rents, royalties and income from similar sources.. | ||||||
| b | Unrelated business taxable income (less section 511 taxes) from businesses acquired after June 30, 1975. | ||||||
| c | Add lines 10a and 10b. | ||||||
| 11 | Net income from unrelated business activities not included in line 10b, whether or not the business is regularly carried on. | ||||||
| 12 | Other income. Do not include gain or loss from the sale of capital assets (Explain in Part IV.) | ||||||
| 13 | Total support (Add lines 9, 10c, 11 and 12.). | ||||||




| Facts And Circumstances Test |
|---|
| Explanation |
|---|
| Software ID: | |
| Software Version: |
Attach to Form 990 or 990-EZ.| Identifier | Return Reference | Explanation |
|---|---|---|
| Program Service Accomplishments(1) | Part III, Line 4a-4d(1) | Line 4a: Research: amfAR supports research projects that explore novel approaches to scientifically sound but untested hypotheses in all areas of research on HIV/AIDS, funding goal-oriented studies that often lack the preliminary data required for support from traditional grant-makers. The Foundation plays a vital role in HIV/AIDS research, identifying critical gaps in knowledge and providing essential seed money that enables grantees and fellows to test the merits of new concepts or technologies that subsequently can be validated through large-scale studies, such as those funded by the National Institutes of Health. amfAR fellowships allow talented young investigators to conduct original investigations under the guidance of experienced scientists, helping to ensure the long-term vitality of AIDS research. New Grants and Fellowships Grants and fellowships are awarded through a rigorous process of peer review by a team of independent HIV/AIDS experts drawn largely from the volunteer scientists on amfAR's Scientific Advisory Committee. Guided by its scientific advisors and with the approval of its board of trustees, amfAR pursues a strategic research plan that focuses on the treatment, prevention, and cure of HIV/AIDS. In 2011, amfAR awarded 22 new grants and fellowships totaling $3,040,608. Four researchers received Mathilde Krim Fellowships in Basic Biomedical Research, an initiative that provides funding for exceptional young researchers who are new to the field of HIV/AIDS research. The initiative has already achieved spectacular results, including numerous published studies in major scientific journals. The 2011 Krim Fellows-each of whom received $125,000-are working on new ways to treat HIV/AIDS and its associated conditions, as well as an HIV vaccine. Among the 2011 fellows is Nicholas Maness, Ph.D., of the University of Wisconsin-Madison, whose aim is to discover new proteins to act as targets for an HIV vaccine. All of the standard methods for making a vaccine, and even new ones not previously tried for any other disease; have so far failed to generate a product that can reduce the risk of HIV infection. Vaccines normally work by inducing immune responses against proteins associated with the virus they are intended to block. Dr. Maness believes there are previously undiscovered HIV proteins, and that the virus also makes proteins in a backwards (technically known as antisense) orientation. He will test for the presence and function of such novel HIV proteins to determine whether they may serve as the basis for a vaccine. Placing the search for a cure for HIV/AIDS at the center of its research efforts, the Foundation launched the amfAR Research Consortium on HIV Eradication (ARCHE) in 2010. Building on momentum from its first round of cure-focused grants issued last year, amfAR announced a second round of grants in 2011 to enable some teams to continue their groundbreaking research while adding two additional, promising projects aimed at unlocking more information about how to potentially eradicate HIV infection. |
| Program Service Accomplishments(2) | Part III, Line 4a-4d (2) | Line 4a, Continued - The second round of funding, totaling $1,042,000 went to five collaborative teams of researchers working in three areas considered central to HIV eradication: the search for a sterilizing cure to eliminate HIV from the body; the search for a functional cure to suppress the virus without treatment; and the characterization of viral reservoirs, which present an obstacle to a cure. Dr. Adriana Andrade of Johns Hopkins University, new to the ARCHE consortium, is testing the ability of disulfiram-a drug approved by the US Food and Drug Administration to treat alcoholism-to drive the virus out of infected cells in a small clinical study. Dr. Bob Siliciano, during his first year of ARCHE funding, identified and characterized the drug as an agent that might flush virus out of latently HIV-infected cells. Collaborating with Dr. Janice Clements, also of Johns Hopkins, he is investigating other FDA-approved drugs for their effect on latent HIV during his second year of funding. Also among this year's ARCHE grantees, Dr. Mike McCune of the University of California, San Francisco, collaborating with Dr. Steven Deeks, is examining the role of ongoing activation of the immune system-long suspected of playing a role in HIV disease-in the ability of HIV to persist during the lifetime of an infected patient. They will also test an FDA-approved drug that could play an integral role in a potential new therapeutic strategy that could bring us closer to a functional cure. Collaborating with the ARCHE investigators at UCSF, including Drs. Steven Deeks and Frederick Hecht, second-time ARCHE grantee Dr. Sarah Palmer of the Swedish Institute for Infectious Disease Control and Karolinska Institute continues to investigate which cellular reservoirs are most responsible for the persistence of HIV. These findings will inform efforts by the Siliciano/Clements and McCune/Deeks ARCHE groups by identifying the important targets of their efforts to purge reservoirs of virus or to modulate immune activation to effect a cure. The other new ARCHE grantee, Dr. Una O'Doherty of the University of Pennsylvania, is comparing methods for measuring HIV reservoir size to determine which are the most accurate and practical. The persistent reservoir of virus constitutes a tiny fraction of all virus present, but understanding how to measure changing levels of virus in the reservoir is difficult-and crucial to determining the next steps in HIV eradication. Published Research Research studies make the greatest impact on the AIDS field and on the broader scientific community when they are published in scientific journals. In the past year, at least 34 scientific publications resulted from amfAR-funded research. These covered current and past targeted areas of research interest. In the Lab, Recreating HIV's Hidden Reservoirs One major obstacle to curing HIV is the persistence in tissues of latent virus that is resistant to attack by current antiretroviral therapy (ART). Recent studies-including several published by amfAR grantees-have documented encouraging progress in the search for the reservoirs where virus persists. But even after zeroing in on HIV's hiding places, scientists need simple, clinically relevant test-tube models for testing new means of attacking the virus in these reservoirs. Dr. Alberto Bosque, one of amfAR's 2009 Mathilde Krim Fellows in Basic Biomedical Research, has helped to develop one such system. Writing in the January issue of the research journal Methods, Bosque and his mentor, Dr. Vicente Planelles, of the University of Utah, reviewed problems with older models of HIV latency. The authors concluded that no single test-tube or animal model for HIV latency is likely to capture the broad spectrum of means by which HIV hides or becomes activated. But their new system brings us one step closer to defining critical factors involved in maintaining latent HIV, with the ultimate aim of rationally designing drugs to destroy such viruses. An Animal Model for a Functional Cure for AIDS Writing in the August issue of PLoS Pathogens, a prestigious online journal, amfAR grantee Dr. Cristian Apetrei and colleagues described a functional cure of SIV, the simian counterpart of HIV, in rhesus monkeys. A functional cure controls the virus at extremely low levels in the body while a sterilizing cure entirely eliminates the virus from the body. Several critical pieces of the HIV disease puzzle have been addressed by their study. First, it shows that the immune system, through the CD8+ "killer" T cell, contributes to the control of an HIV-like infection. Second, it suggests that the chronic immune activation characteristic of HIV infection, even in those patients whose virus is seemingly well-controlled with drugs, is the result of incomplete suppression of virus. And unless such low levels of continuous virus growth can be blocked, it may preclude restoration of normal immunity. As Apetrei and associates appropriately concluded, their model provides the opportunity for further investigation into the phenomenon of "super-elites," which should enable "design of new approaches for controlling HIV infection" and help make a functional cure a reality. The Ethics of Universal HIV Screening Seeking to encourage earlier and more widespread HIV testing, in 2006 the U.S. Centers for Disease Control and Prevention (CDC) recommended an "opt-out" approach to testing, whereby healthcare workers would inform patients that they would be tested unless they declined. The aim of the new guidelines was to expand the number of HIV infections being diagnosed-considered a key to slowing the spread of the virus-and to get people into treatment earlier, thereby reducing the level of virus in their bodies and rendering them less infectious to others. Yet few national professional organizations have endorsed this recommendation. amfAR-supported researcher Dr. Roland Merchant of Brown University, writing in the American Journal of Bioethics, addresses the ethical concerns surrounding such testing. Merchant and colleagues concluded that if properly implemented, the CDC recommendations on universal testing could benefit both individuals and society. They emphasized that patients must be informed clearly that testing will take place, provided with informational materials about HIV and HIV testing, and told that they have the right to refuse testing. If the new HIV testing recommendations are otherwise ethically acceptable, their adoption should require only these sorts of safeguards to assure they are properly implemented. New Targeted RFP amfAR issued a request for proposals (RFP) in September 2011 for biomedical research projects relevant to exploring the mechanisms for HIV persistence and the potential for HIV eradication. Think Tanks and Conferences In April 2011, amfAR co-sponsored a think tank in Baltimore that brought together more than 50 leading academic researchers, government scientists, regulators, and community advocates to identify steps that can be taken to hasten the progress of cure-related research. And in July, amfAR Vice President and Director of Research Dr. Rowena Johnston co-chaired-with Nobel Prize winning scientist Dr. Franoise Barr-Sinoussi-"Controversies in HIV Cure Research," a panel discussion held in conjunction with the International AIDS Society conference in Rome. |
| Program Service Accomplishments (3) | Part III, Line 4a-4d (3) | Line 4b: TREAT ASIA: amfAR's TREAT Asia program (Therapeutics Research, Education, and AIDS Training in Asia) involves a network of hospitals, clinics, and research institutions working with civil society to ensure the safe and effective delivery of HIV/AIDS treatments across Asia and the Pacific. The TREAT Asia Network encompasses 22 adult and 20 pediatric sites throughout the region, which collaborate on a variety of projects. Eight papers based on the network's research were published in U.S. and international scientific journals in 2011. TREAT Asia HIV Observational Database (TAHOD) TREAT Asia pioneered the region's first adult observational database for HIV/AIDS, which now includes anonymous data collected from more than 5,500 patients at 22 clinical sites in 12 countries. The information gathered and analyzed through the database informs the development of more effective research and treatment programs, and helps define treatment standards specific to HIV/AIDS in Asia. TREAT Asia Pediatric Network Representing more than 5,000 HIV-positive children in Asia, TREAT Asia's Pediatric Network includes 20 sites in seven countries; these sites share information and best practices in an effort to improve the quality of pediatric care in the region. The TREAT Asia Pediatric HIV Observational Database (TApHOD) was modeled on the adult TAHOD program, and includes data from approximately 4,000 pediatric patients at 16 clinical sites in Cambodia, India, Indonesia, Malaysia, Thailand, and Vietnam. International AIDS Database TREAT Asia manages the Asia-Pacific section of the International Epidemiologic Databases to Evaluate AIDS (IeDEA), a global collaboration established by the U.S. National Institute of Allergy and Infectious Diseases. To support IeDEA, TREAT Asia is contributing anonymous data from approximately 13,600 patients at 60 clinical centers in 13 countries within Asia and Australia. Investing in Adolescent Research TREAT Asia is currently supporting three studies that it hopes will inform and improve adolescent HIV treatment and care in Southeast Asia. This first is examining the incidence of human papillomavirus (HPV) infection?a precursor to cervical and anal cancer?in HIV-positive adolescents. A second study is assessing bone mineral density levels in children living with HIV and finding preliminary correlations between the use of antiretroviral therapy and bone density loss. The third study is using an audio-computer-assisted survey instrument (ACASI) to better understand how adolescents experience living with HIV by allowing them to anonymously respond to questions using a computer interface. Reaching Out to MSM In 2011, TREAT Asia became a proud co-sponsor of www.adamslove.org, a new non-commercial website providing HIV/AIDS information to men who have sex with men (MSM) in Thailand. An initiative of the Thai Red Cross AIDS Research Centre, Adam's Love innovatively combines education and entertainment, and is the first website of its kind in Southeast Asia. The website's creative team has partnered with amfAR to explore initiating a similar "edutainment" website in Indonesia. Exploring Links Between HIV and Cancer Among HIV-positive MSM, the risk of anal cancer is twice the level of those who are HIV-negative, but little research has been done on this issue in Asia. With funding from IeDEA, in 2009 TREAT Asia began supporting an innovative research study exploring the links between HIV and anal cancer and looking at cancer biomarkers in an attempt to better identify MSM with pre-cancerous anal lesions. Building Research Capacity TREAT Asia has implemented a research education program to help network members strengthen their skills in conducting clinical research and to boost the overall quality of care in the region. TREAT Asia organized 13 workshops and training sessions in 2011 including sessions on basic research skills (e.g., ethics, biosafety, research methods), laboratory training (e.g., HIV drug resistance testing), and clinical management of HIV (e.g., cancer, treatment failure, care of MSM). Building Community Treatment Literacy and Promoting Advocacy for Treatment Access Communicating treatment information about a disease as complex as HIV/AIDS can be daunting, but patients' lives depend on it. TREAT Asia works closely with regional organizations to support treatment literacy activities, including the production of "community friendly" educational brochures on HIV treatment standards in local languages. TREAT Asia also continues its partnership with UNAIDS, the Asia-Pacific Network of People Living with HIV/AIDS, the International Treatment Preparedness Coalition, and the Mdecins Sans Frontires Access Campaign. Through the Asia Treatment Working Group, TREAT Asia is part of a platform for promoting treatment access and higher quality HIV healthcare within the region. In 2011, TREAT Asia continued to publish lay-language articles about new research in the fields of prevention, treatment, and basic science. The goal of these articles is to explain HIV/AIDS research advances for people living with HIV/AIDS and their families, communities, and caregivers across Asia. The articles appear in the TREAT Asia Report and on TREAT Asia's website, www.treatasia.org. XVIII International AIDS Conference TREAT Asia was well represented at the International AIDS Society Conference in July 2011 in Rome, Italy, where several network members and partners presented their research findings. In addition, TREAT Asia was a scientific co-sponsor of the 3rd International Workshop on HIV Pediatrics, which preceded the conference. 14th Bangkok Symposium on HIV Medicine amfAR continued its support of this annual regional symposium, which was held in January 2011 and was organized by HIV-NAT, a TREAT Asia network site. |
| Program Service Accomplishments (4) | Part III, Line 4a-4d (4) | Line 4c: EDUCATION AND INFORMATION: amfAR seeks to translate and disseminate information on important AIDS-related research, treatment, prevention, and policy issues for diverse audiences and to stimulate broad awareness of the need for better treatment and prevention methods. amfAR also publishes a wide range of educational materials, maintains an informative website, and engages respected public figures, HIV/AIDS scientists, and policy makers in communicating the need for continued research to develop new methods of prevention, treatment, and, ultimately, a cure for AIDS. amfAR25 amfAR commemorated 25 years of operation in 2011 and marked the occasion with a range of events and activities. The Foundation adopted the tagline "Making AIDS History" for the year and incorporated it into a special commemorative logo. Three short films were produced to commemorate the anniversary. One of them, narrated by amfAR Global Fundraising Chairman Sharon Stone, traced amfAR's history and showcased the Foundation's achievements. The other two were narrated by Vanessa Redgrave and paid tribute to the Foundation's founders - Dr. Mathilde Krim and Dame Elizabeth Taylor. Ironically, and tragically, Dame Elizabeth passed away in March of 2011. A special website - www.makingaidshistory.org - was created to capture the personal stories of a diverse group of people living with HIV from different backgrounds and different parts of the country. The site and the stories stimulated media interest and coverage of the individuals in local outlets in several parts of the country. Educational Materials amfAR produces a range of periodicals in both print and electronic formats, including its newsletter Innovations, published twice a year and distributed to more than 40,000 people; the TREAT Asia Report, published and distributed three times a year to more than 4,000 readers in the international health community; and a monthly e-mail newsletter distributed to more than 40,000 people. The Foundation's website features news, interviews, and original articles covering science, policy, the global epidemic, and amfAR programs and activities. amfAR also creates and distributes program reports, press releases, and updates on major HIV/AIDS issues, and conducts public service advertising campaigns that have been instrumental in educating policy makers, healthcare professionals, people with HIV/AIDS, and the general public. Social Media amfAR vigorously expanded its presence in the social media arena, reaching large numbers of a people and a generally younger demographic that is often less educated about HIV and the AIDS epidemic. The Foundation regularly added content to its Facebook page, mounted a campaign to increase Facebook followers, and live tweeted from fundraising and program events. It also expanded its YouTube channel content with a range of educational videos. Media Outreach amfAR continued to work closely with the media to raise the profile of HIV/AIDS, both domestically and internationally, and to help ensure the accuracy of AIDS press coverage. Articles and reports involving amfAR-many of which included interviews with amfAR spokespeople-were carried in numerous media outlets, including The New York Times, The Wall Street Journal, the Washington Post, New York magazine, Reuters, Bloomberg News, and The Huffington Post. amfAR's leadership role in AIDS research was highlighted in late November 2010, when the iPrEx study results were released and outlets including The New York Times, The Wall Street Journal, the Financial Times, Agence-France Presse, and PBS NewsHour relied on amfAR CEO Kevin Frost or Vice President and Director of Public Policy for Chris Collins for commentary on what the results meant for the future of HIV/AIDS prevention and research. amfAR's public awareness efforts are greatly enhanced by the committed support of public figures who lend their voices and donate their time, talents, and resources to help sustain the Foundation's mission. Support of amfAR by prominent public figures began with the late Dame Elizabeth Taylor, and others have followed in her footsteps. amfAR is profoundly grateful for the continuing steadfast support of Global Fundraising Chairman Sharon Stone. In 2011, celebrity supporters included amfAR Ambassadors Cheyenne Jackson, Milla Jovovich, Liza Minnelli, and Michelle Yeoh, as well as Janet Jackson, Kylie Minogue, Dita Von Teese, Heidi Klum, Alan Cumming, Stevie Wonder, Gladys Knight, Dionne Warwick, Elton John, Richard Gere, Rosie O'Donnell, Whoopi Goldberg, Jennifer Hudson, John Legend, Andy Cohen, Diane Kruger, Kathy Griffin, Kim Cattrall, Stanley Tucci, and Rufus Wainwright. |
| Program Service Accomplishments (5) | Part III, Line 4a-4d (5) | THE MSM INITIATIVE: amfAR's MSM Initiative was launched in 2007 to respond to the alarmingly high rates of HIV among MSM, a group that in low- and middle-income countries is on average 19 times more likely to be infected than the general population. Stigma, discrimination, and legal prohibitions have fueled the spread of the epidemic among MSM, most of whom do not have access to HIV prevention, treatment, and care services. The MSM Initiative aims to reduce the spread and impact of HIV infection among MSM in resource-limited countries by providing support to grassroots groups through its community awards program. The program also works to raise awareness of HIV among MSM and to advocate increased funding for MSM-targeted services. Community Awards In 2011, amfAR awarded more than $775,000 to 44 groups in Africa, Asia and the Pacific, the Caribbean, Eastern Europe and Central Asia, and Latin America for a wide range of projects addressing HIV prevention, outreach, education, advocacy, testing, research, and capacity building. Africa amfAR awarded funding to eight groups in Africa: Humanity First Cameroon and Alternatives-Cameroun; an unnamed group in Ethiopia (name withheld by request); PEMA Kenya; Stop AIDS In Liberia; Association de lutte contre le sida (Morocco); Gender DynamiX (South Africa); and Gays and Lesbians of Zimbabwe. PEMA Kenya (Mombasa, Kenya) Building upon a previous amfAR award, PEMA Kenya is addressing stigma, discrimination, and criminalization of MSM and LGBT individuals among the religious community and media and law enforcement professionals in coastal Kenya. Emphasis is placed on the implications of stigma in accessing HIV prevention and treatment and other health services. Asia-Pacific Eleven organizations in Asia and the Pacific received community awards in two separate rounds of awards: Loving Support Center for Health and Education and another unnamed group in China; AIDS Task Force of Fiji; Sangama (India); Youth for Health Center (Mongolia); TLF Sexuality, Health and Rights Educators Collective, Incorporated (Philippines); The Human Rights Education Institute of Burma (Thailand); Beijing Ark of Love PLWHA Supporting Group (China); PT Foundation (Malaysia); AIDS Awareness Society (Pakistan); and Vietnamese Community Mobilisation Center for HIV/AIDS Control (Vietnam). Loving Support Center for Health and Education (China) This direct service intervention is promoting the health and rights of male sex workers in Shenyang and Tianjin. Employing a rights-based approach, the project empowers sex workers to assist and support each other, builds skills for health and well-being, and provides STI/HIV information and referrals. The project is also producing the first-ever male sex worker periodical in China. Caribbean Nine grassroots organizations in the Caribbean received amfAR funding: United Belize Advocacy Movement; Centro de Orientacin e Investigacin Integral in partnership with Jvenes de la Vida Real (Dominican Republic); GrenCHAP Inc. (Grenada); two unnamed organizations in Jamaica; United and Strong, Inc. (Saint Lucia); Foundation HE + HIV (Suriname); MSM: No Political Agenda and Friends For Life (Trinidad and Tobago). Friends For Life (Trinidad & Tobago) This project utilizes trained peer educators to increase access to sexual health services (including HIV voluntary counseling and testing) for LGBT individuals, other MSM, and transgender and male sex workers. Central to the project is the distribution of condoms, lubricant, safer sex information, and referral information cards. The project also collects baseline data on HIV/AIDS prevention knowledge among MSM, and provides one-to-one coping and life-skills counseling for gay men, other MSM, transgender individuals, and sex workers. Eastern Europe and Central Asia Nine groups in Eastern Europe and Central Asia received community awards from amfAR's MSM Initiative: We For Civil Equality (Armenia); Center for Information and Counseling on Reproductive Health - Tanadgoma (Georgia); Kyrgyz Indigo (Krgyzstan); The Siberian Alternative Center (Russia); Oryol Regional Public Organization to Fight AIDS, Phoenix PLUS (Russia); Non-Governmental Organization Safe Pulse of Youth (Serbia); Civil Society Organization Equal Opportunities (Tajikistan); Nikolaev Regional Public Youth Movement Penitentiary Initiative and NGO Insight (Ukraine). The Siberian Alternative Center NGO (Russia) Building upon a previous amfAR award, this project engages female friends of gay men, other MSM, and transgender individuals as counselors and educators. Taking advantage of the special relationship that exists between MSM/transgender individuals and their female friends, through training and regular meetings these women will assist in providing effective behavior change communication to reduce risky sexual behavior among MSM/TG. Latin America Seven organizations in Latin America received community awards: VIVO POSITIVO (Chile); Fundacin Radio Diversia (Colombia); Asociacin Jvenes en Movimiento (Honduras); SOMOSGAY (Paraguay); VA LIBRE in partnership with Asociacin Amigos por Siempre Promoviendo Tus Derechos AAxS (Peru); Instituto de Estudios en Salud, Sexualidad y Desarrollo Humano (Peru); Asociacin Civil Manantial de Vida Pro Defensa de los Derechos Humanos (Venezuela). Asociacin Civil Manantial de Vida Pro Defensa de los Derechos Humanos (Venezuela) This direct service intervention aims to empower young gay Yukpa men through skills-building workshops, discussion groups, and the development of a culturally appropriate HIV prevention and life skills handbook. Global Advocacy Corps Awards The Global Advocacy Corps is a small grants program shared by the Public Policy and MSM Initiative programs of amfAR. The advocacy work funded through this program emphasizes the use of new evidence and tools, and more strategic approaches to tackling the epidemic on a national level. It supports development of analyses and other writing, as well as follow-through advocacy with government, donors, and communities. A central goal of the awards is to affect national and donor policy: to make national responses to HIV/AIDS better funded, more strategic, more ambitious in terms of public health impact, and more focused on outcomes for individuals and communities affected by HIV/AIDS. It is expected that grantees draw on the latest research to make the case for new and smarter investments to improve HIV-related results. Two Global Advocacy Corps awards totaling $40,000 were made to groups in Kenya and Namibia in 2011. Publications As part of its efforts to raise awareness among governments, donors, and international nongovernmental organizations of the spread of HIV among MSM and to advocate effective strategies for addressing it, amfAR publishes reports on HIV and MSM. In 2011, the MSM Initiative staff worked with the Policy team and colleagues at Johns Hopkins University to compile and edit an MSM global report-titled "Achieving an AIDS-Free Generation for Gay Men and Other MSM"-which finds that resources dedicated to addressing the epidemic among MSM are grossly insufficient, and that funding intended for this population is often diverted away from MSM-related services. The report was released in 2012. |
| Program Service Accomplishments (6) | Part III, Line 4a-4d (6) | public policy: Informed by thorough research and analysis, amfAR is a highly respected advocate of rational and compassionate AIDS-related public policy. The Foundation is engaged in efforts to secure necessary increases in funding for HIV/AIDS research; implement the new National HIV/AIDS Strategy; expand access to care and treatment; and protect the civil rights of all people affected by HIV/AIDS. Capitol Hill AIDS Summit Spearheaded by Senior Medical and Policy Advisor Susan Blumenthal, amfAR brought together many of the biggest names in HIV research, policy, and advocacy for a half-day conference that filled the Senate Kennedy Caucus Room to capacity. Speakers and panelists included Dr. Anthony Fauci of the National Institutes of Health; Melody Barnes, director of the White House Domestic Policy Council; Dr. Michel Kazatchkine, executive director of the Global Fund; and Dr. Margaret Hamburg, commissioner of the FDA. Speakers discussed ideas and strategies for halting the epidemic, and Whoopi Goldberg, Cokie Roberts, and Chris Matthews lent their star power to help focus the day's message: ending the AIDS epidemic. House Democratic Leader Nancy Pelosi (D-CA), along with Reps Barbara Lee (D-CA), Henry Waxman (D-CA), Nita Lowey (D-NY), and Jim Himes (D-CT), as well as Senators Kirsten Gillibrand (D-NY) and Mike Enzi (R-WY) all made appearances to strongly voice their continued support for amfAR and the fight against AIDS. Harm Reduction As one of the earliest supporters of comprehensive harm reduction programs for injection drug users (IDUs), including syringe exchange, amfAR has played a leading role in advocating the implementation of these lifesaving programs. In December 2009, the Foundation celebrated a major victory on this front when Congress lifted the ban on federal funding for syringe exchange programs (SEPs). However, in anticipation of a House proposal to reinstate the ban on federal funds for syringe access, amfAR's public policy office worked throughout1 2011with Senate Foreign Operations and Financial Services staff and Senator Sherrod Brown's office on this issue. amfAR staff made a presentation on US drug policy and organized a meeting of PEPFAR intravenous drug users (IDU) implementers at the Beirut Harm Reduction Conference. And in March, the policy team organized and attended meetings with staff to key Senators and House Minority Leader Pelosi. Also in March, amfAR staff hosted a strategy meeting in Congress on syringe exchange. amfAR funds the only annual national survey of U.S. SEPs, which is traditionally published in the Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report (MMWR). Under contract with the New York State Department of Health's AIDS Institute, amfAR continued to administer the distribution of harm reduction supplies to the 20 authorized SEPs statewide, which have served more than 155,000 registered participants. Shaping the Domestic Response to HIV/AIDS amfAR has long advocated the implementation of a comprehensive national HIV/AIDS strategy to address the ongoing epidemic in the U.S., where more than one million people are living with the virus. In 2011, public policy staff members attended a U.S. Department of Health & Human Services (HHS) meeting on redesigning reporting requirements for federal grant recipients so they are aligned with the national strategy, which was unveiled by the White House in July 2010 and emerged with help from the HIV/AIDS advocacy community. amfAR staff also spearheaded a sign-on statement-signed by more than 140 organizations-supporting the national strategy and laying out several principles for its success, including calls for expanded services and protection of Medicaid expansion and health reform. Public policy staff were also featured in a White House video on the first anniversary of the national strategy. Global Health In 2011, public policy staff worked with fellow AIDS advocates to argue against funding cuts for global HIV/AIDS initiatives, including the President's Emergency Plan for AIDS Relief (PEPFAR) and the Global Fund to Fight AIDS, Tuberculosis and Malaria, and focused on the need to scale up HIV prevention efforts, both domestically and globally, as an effective way to combat the worldwide AIDS epidemic. In addition to meeting with key administration officials and members of Congress, amfAR released a series of publications arguing against the case for cutting global AIDS funding. In July 2011, the Foundation released two new issue briefs: "Ending the HIV/AIDS Epidemic" drew on the latest research to make the case that with strategic investments we can make great strides against the epidemic; "FY12 Global Health Funding Proposals: Projecting the Human Impact" estimated the human impact of various budget scenarios. In February, the public policy office released a report showing the potential human impact of global health funding cuts as proposed in September 2010 by House Minority Leader John Boehner. Vertical Transmission Preventing hundreds of thousands of HIV-positive mothers from passing the virus to their children "is one of the startling successes in the response to the global AIDS epidemic," said amfAR Vice President and Director of Public Policy Chris Collins in his opening remarks at an amfAR-sponsored Capitol Hill briefing on January 31. Recognizing these extraordinary gains-and the imperative of extending these gains further-a panel of experts at the Washington, D.C., briefing highlighted the challenges to fully eradicating mother-to-child HIV transmission The briefing brought together experts from the U.S. government, foundations, and NGOs that sponsor prevention of mother-to-child transmission (PMTCT) services. MSM amfAR's policy office works closely with the MSM Initiative to advocate expanded access to HIV prevention and treatment services for MSM worldwide, and to fight the stigma and discrimination that make MSM more vulnerable to HIV infection and inhibit equal access to care. Working with Trust for America's Health, amfAR released an issue brief proposing "A New HIV Prevention Paradigm for Gay and Bisexual Men in the U.S.," emphasizing efforts to address the context of risk, including expanded HIV treatment access to reduce community viral load, and anti-discrimination, anti-stigma, and anti-bullying efforts. Policy staff also co-sponsored, with Advocates for Youth, a community forum on Sexual Rights and HIV Prevention in Nigeria featuring activist Stephen Chukwumah and presented at a COC Netherlands conference in Moldova on opportunities for funding and policy change for LGBT groups in the region. When Ugandan MSM advocate David Kato was brutally murdered in January, amfAR put out a release calling for an independent investigation and policy staff utilized social media to call on the US State Department to press the Ugandan government to fully investigate the murder. A "Prevention Revolution" Advocating increased funding for lifesaving HIV/AIDS research is another of amfAR's policy priorities. In March 2011, amfAR sponsored a Capitol Hill briefing-titled "Accelerating an HIV Prevention Revolution: A Roadmap"-that was attended by more than a dozen leading government, research, policy, and medical experts. Citing major advances during the past year in pre-exposure prophylaxis (PrEP) and microbicide trials, strides in vaccine research, the use of social media, and treatment as a means of preventing viral transmission, the speakers-including high-level representatives from the Centers for Disease Control and Prevention (CDC), UNAIDS, the National Institutes of Health (NIH), and the San Francisco Department of Public Health-stressed that, 30 years into the epidemic, the world finds itself in a new era of prevention. Many of the speakers touched on the global application of new HIV prevention techniques, and underscored the importance of further study and funding for these initiatives. Pre-Exposure Prophylaxis Pre-exposure prophylaxis (PrEP)-which involves giving antiretroviral therapy to HIV-negative people at high risk of becoming infected-holds great promise as a potential prevention intervention. In 2011, amfAR, as part of a coalition of partners, organized and participated in calls, meetings, and forums while continuing to encourage regulatory approval of PrEP for MSM domestically. |
| Policies | Form 990, Part VI, Section B | Line 11 - The Form 990 was prepared by a nationally renowned accounting firm in conjunction with the organization's financial department. A copy of the draft Form 990 was circulated to the full Board of Trustees for discussion and comment. Each Board Member was provided ample opportunity to comment on the information contained in the 990 prior to its filing with the Internal Revenue Service. Line 12 - Each officer, director, trustee and key employee of amFar ("foundation") is required to annually disclose any conflicts of interest that arise by virtue of employment, board service, or position with the foundation. The foundation monitors compliance with its conflict of interest policy through an annual questionnaire/disclosure statement that is distributed to these individuals. Potential conflicts are investigated immediately. LINE 15 -AMFAR ("FOUNDATION FOR AIDS RESEARCH") UNDERTAKES A THOROUGH PROCCESS TO ENSURE THAT THE COMPENSATION IT PAYS TO ITS TOP MANAGEMENT OFFICIAL AND ALL OF ITS OFFICERS AND KEY EMPLOYEES IS REASONABLE GIVEN THE MARKET IN WHICH THE FOUNDATION OPERATES. AN INDEPENDENT CONSULTING FIRM QUALIFIED IN THE AREA OF NONPROFIT COMPENSATION PREPARES AN ANALYSIS OF MARKET COMPENSATION RANGES BY JOB FUNCTION AND PRESENTS IT TO THE COMPENSATION COMMITTEE OF THE BOARD. ON THE BASIS OF THIS INFORMATION, STAFF COMPENSATION IS DETERMINED ACCORDING TO SALARY RANGES APPROVED BY THE COMPENSATION COMMITTEE OF THE BOARD, IN CONSULTATION WITH THE CEO AND CFO. CEO COMPENSATION IS REVIEWED AND DETERMINED BY THE COMPENSATION COMMITTEE OF THE BOARD UTILIZING THE INDEPENDENT CONSULTANT ANALYSIS. |
| Disclosure | Form 990, Part VI, Section C | LIne 19 - amfar makes its Form 990 available to the public by retaining a copy at its place of business and on its website, www.amfar.org. The Form 990 is likewise published on the internet at www.guidestar.org. The Foundation's financial statements are made available in its annual report and on its website. The Foundation's governing documents and conflict of interest policy are not ordinarily made available to the public, but, if requested, will be provided at management's discretion. |
| Functional Expenses | Part IX, Lines 1 & 3 | The Foundation for AIDS Research reports its grants net of grant returns or recoveries. Periodically, grants remitted to charitable organizations are returned to AMFAR for a variety of reason. On Schedules F & I, grants are reported irrespective of whether they were ultimately returned to AMFAR since categorizing the "returned" amounts would be time consuming. Therefore, amounts reported on Part IX, Line 1 will not tie to total grants on Schedule I; amounts reported on Part IX, Line 3 will not tie to total grants on Schedule F. |
| Other Changes in Net Assets | FORM 990, SECTION XI, LINE 5 | UNREALIZED LOSS.............(465,956) OTHER CHANGES................135,728 ------------ TOTAL LINE 5 (330,228) ============ |
| Software ID: | |
| Software Version: |